Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C17H22N4O2 |
| Molecular Weight | 314.3822 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
NC1=NC=C(C[C@@H](C(O)=O)C2=CN(C=N2)C3CCCCC3)C=C1
InChI
InChIKey=XHKJBNCTUYFLDC-CQSZACIVSA-N
InChI=1S/C17H22N4O2/c18-16-7-6-12(9-19-16)8-14(17(22)23)15-10-21(11-20-15)13-4-2-1-3-5-13/h6-7,9-11,13-14H,1-5,8H2,(H2,18,19)(H,22,23)/t14-/m1/s1
| Molecular Formula | C17H22N4O2 |
| Molecular Weight | 314.3822 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 12:04:45 GMT 2023
by
admin
on
Sat Dec 16 12:04:45 GMT 2023
|
| Record UNII |
AMA3SE8GEH
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
69083065
Created by
admin on Sat Dec 16 12:04:45 GMT 2023 , Edited by admin on Sat Dec 16 12:04:45 GMT 2023
|
PRIMARY | |||
|
1375150-73-4
Created by
admin on Sat Dec 16 12:04:45 GMT 2023 , Edited by admin on Sat Dec 16 12:04:45 GMT 2023
|
PRIMARY | |||
|
AMA3SE8GEH
Created by
admin on Sat Dec 16 12:04:45 GMT 2023 , Edited by admin on Sat Dec 16 12:04:45 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
SAR126119
Company: Sanofi
Description: TATA box binding protein associated factor RNA polymerase 1A (TAF1A) inhibitor
Molecular Target: TATA box binding protein associated factor RNA polymerase 1A (TAF1A)
Latest Stage of Development: Phase I
Standard Indication: Stroke
Indication Details: Treat acute ischemic stroke
|
||
|
ACTIVE MOIETY |
Originator: Sanofi; Class: Anti-ischaemics; Mechanism of Action: Carboxypeptidase U inhibitor; Orphan Drug Status: No; On Fast track: No; Highest Development Phase: Phase I for Stroke; Most Recent Events: 08 Jan 2013 Phase II development is ongoing in France, 31 Dec 2011 Sanofi completes a phase I trial in Stroke in France during 2011, 28 Jul 2011 Phase-I clinical trials in Stroke in France (unspecified route)
|
